生物标志物检测技术在指导食管癌新辅助治疗中的应用

doi:10.3760/cma.j.issn.1673-422X.2015.12.011

摘要/Abstract

摘要： 目前，运用生物标志物预测食管癌新辅助治疗疗效技术已广泛应用于临床。生物标志物检测途径众多，主要包括免疫组织化学检测、血清标志物检测和常规血液检查等传统检测技术，以及基因表达谱分析、单核苷酸多态性分析、miRNA检测、蛋白质组学分析等新兴技术。随着生物技术的发展，生物标志物检测技术有望成为评估食管癌新辅助治疗疗效、风险、预后以及选择个体化治疗方案的有效手段。

关键词: 食管肿瘤, 生物学标记, 肿瘤辅助疗法

Abstract: At present, the technology to predict the response to neoadjuvant therapy with biomakers has been widely used in clinical practice. The approaches of biomarkers detection are various, including immunohistochemistry, detection of serum biomarkers conventional blood tests, gene expression profile analysis, single nucleotide polymorphisms, miRNAs, proteomics analysis. With the development of biotechnology, the technology of biomarkers detection is expected to become effective means in assessment of adjuvant therapy, risk, prognosis and individualization in esophageal cancer treatment.

Key words: Esophageal neoplasms, Biological makers, Neoadjuvant therapy

李晨,程玉峰. 生物标志物检测技术在指导食管癌新辅助治疗中的应用[J]. 国际肿瘤学杂志, 2015, 42(12): 924-927.

Li Chen, Cheng Yufeng. Applications of the biomakerdetection technology guiding neoadjuvant therapy for advanced esophageal cancer[J]. Journal of International Oncology, 2015, 42(12): 924-927.

参考文献

［1］ Bollschweiler E, Hlscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer［J］. Future Oncol, 2010, 6(1): 25-35. ［2］ Nguyen NP, Krafft SP, VinhHung V, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to threedimensional radiotherapy［J］. Radiother Oncol, 2011, 101(3): 438-442. ［3］ Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival［J］. J Clin Oncol, 2005, 23(19): 4330-4337. ［4］吕雅蕾，刘巍，左静，等． ERCC1、ERCC2与食管癌临床病理特征和预后关系的研究［J］．临床肿瘤学杂志， 2010， 7（7）： 600-604．［5］ Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin［J］. Ann Surg Oncol, 2012, 19(3): 757-765. ［6］ Vallbhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer［J］. Dis Esophagus, 2006, 19(6): 425-432. ［7］ Yasunaga M, Tabira Y, Nakano K, et al. Accelerated growth signals and low tumorinfiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma［J］. Ann Thorac Surg, 2000, 70(5): 1634-1640. ［8］郑成义，王朝阳，闻吉军，等．食管鳞癌中NFκB、p53的表达及其与新辅助化疗敏感性的关系［J］．现代肿瘤医学， 2009， 12（12）： 2328-2330．［9］ Brabender J, Metzger R, Vallbhmer D, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer［J］. Surgery, 2012, 151(2): 306-312. ［10］ Makuuchi Y, Honda K, Osaka Y, et al. Soluble interleukin6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy［J］. Cancer Sci, 2013, 104(8): 1045-1051. ［11］ Grimminger P, Vallbhmer D, Hoffmann A, et al. Quantitative analysis of survivin RNA expression in blood as a noninvasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer［J］. J Surg Oncol, 2009, 100(6): 447-451. ［12］李杰．食管癌放疗前后多种生物标志物联合检测的临床意义［J］．肿瘤研究与临床， 2009， 12（21）： 837-839．［13］ Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional bloodborne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer［J］. Med Oncol, 2013, 30(3): 596. ［14］ Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation［J］. J Clin Oncol, 2006, 24(2): 259-267. ［15］ Duong C, Greenawalt DM, Kowalczyk A, et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer［J］. Ann Surg Oncol, 2007, 14(12): 3602-3609. ［16］ Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer［J］. Ann Surg, 2009, 250(5): 729-737. ［17］ Metzger R, Heukamp L, Drebber U, et al. CUL2 and STK11 as novel responsepredictive genes for neoadjuvant radiochemotherapy in esophageal cancer［J］. Pharmacogenomics, 2010, 11(8): 1105-1113. ［18］ Motoori M, Takemasa I, Yamasaki M, et al. Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples［J］. Int J Oncol, 2010, 37(5): 1113-1120. ［19］ Glinsky GV. Integration of HapMapbased SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes［J］. Cell Cycle, 2006, 5(22): 2613-2625. ［20］ Metzger R, WarneckeEberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis［J］. J Gastrointest Surg, 2012, 16(1): 26-34; discussion 34. ［21］ Bradbury PA, Kulke MH, Heist RS, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes［J］. Pharmacogenet Genomics, 2009, 19(8): 613-625. ［22］ Bhatti I, Lee A, Lund J, et al. Small RNA: a large contributor to carcinogenesis?［J］. J Gastrointest Surg, 2009, 13(7): 1379-1388. ［23］ Maru DM, Singh RR, Hannah C, et al. MicroRNA196a is a potential marker of progression during Barrett′s metaplasiadysplasiainvasive adenocarcinoma sequence in esophagus［J］. Am J Pathol, 2009, 174(5): 1940-1948. ［24］ Ogawa R, Ishiguro H, Kuwabara Y, et al. Expression profiling of microRNAs in human esophageal squamous cell carcinoma using RTPCR［J］. Med Mol Morphol, 2009, 42(2): 102-109. ［25］ Odenthal M, Bollschweiler E, Grimminger PP, et al. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR192 in prediction of multimodality therapy response［J］. Int J Cancer, 2013, 133(10): 2454-2463. ［26］ Ko MA, Zehong G, Virtanen C, et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy［J］. Ann Thorac Surg, 2012, 94(4): 1094-1102; discussion 1102-1103. ［27］ Ota Y, Takagi Y, Osaka Y, et al. Usefulness of serum protein profiling for prediction of preoperative chemoradiosensitivity of esophageal cancer［J］. Oncol Rep, 2007, 18(3): 653-657. ［28］ Maher SG, Mcdowell DT, Collins BC, et al. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation［J］. Ann Surg, 2011, 254(5): 809-816; discussion 816-817.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[8]	徐放, 朱文钿. 肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[9]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[10]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[11]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[12]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[13]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[14]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[15]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.